No Data
HighTide Therapeutics Enrolls Patients for Phase 3 Clinical Trial of Metabolic, Digestive Diseases Drug
HIGHTIDE-B (02511) has completed the patient enrollment for the HTD1801 head-to-head treatment of Dapagliflozin in a phase III clinical trial for type 2 diabetes.
HIGHTIDE-B (02511) announced that the company's independently developed intestinal and hepatic anti-inflammatory and metabolic regulator ursodeoxycholic acid...
HIGHTIDE-B (02511): Gao Liping has been appointed as the joint company secretary.
HIGHTIDE-B (02511) has announced that due to the need to allocate more time to other work arrangements, Yu Li has submitted...
HighTide Therapeutics to Cooperate on Chronic Diseases, Longevity, Anti-Aging With SSY Group
Express News | HighTide Therapeutics - Unit Entered Into Strategic Co-Operation Framework Agreement With Shijiazhuang No. 4 Pharmaceutical
SSY GROUP (02005.HK) has signed a framework agreement with Junshentai Pharmaceutical for joint research and development.
On December 19, Gelonghui reported that SSY GROUP (02005.HK) announced that its wholly-owned subsidiary, Shijiazhuang Four Pharmaceuticals Co., Ltd., has entered into a strategic cooperation framework agreement with HIGHTIDE-B (02511.HK) and its wholly-owned subsidiary ("Partner"). The agreement aims to combine the group's extensive experience in active screening, formulation development, achievement transformation, quality, and cost control, along with HIGHTIDE-B's unique advantages in the field of natural product multi-system collaborative innovation, to tackle industry challenges and provide breakthrough solutions for Global metabolic diseases and longevity anti-aging.
